Table 3.. Essais randomisés contrôlés de traitements médicamenteux modifiant HDL et impactant les résultats cliniques ou le degré d'athérosclérose en critère de substitution

Abréviations: AFREGS, Armed Forces Regression Study; apo A-1, apolipoprotéine A-l; ARBITER, Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol; BECAIT, Bezafibrate Coronary Atherosclerosis Intervention Trial; BIP, Bezafibrate Infarction Prevention Study; CP coronaropathie ; CDP, Coronary Drug Project; CLAS, Cholesterol Lowering Atherosclerosis Study; CLAS Fern, groupe CLAS de l'athérosclérose fémorale; CLAS IMT, groupe CLAS de la carotide à l'ultrason; DAIS, Diabetes Atherosclerosis Intervention Study; ERASE, Effect of rHDL on Atherosclerosis-Safety and Efficacy Trial; FATS, Familial Atherosclerosis Treatment Study; FIELD, Fenofibrate Intervention and Event Lowering in Diabetes Study; HATS, HDL-Atherosclerosis Treatment Study; HDL-C, cholestérol associé aux lipoprotéines de haute densité; HHS, Helsinki Heart Study; ILLUSTRATE. Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation Trial; EIM, épaisseur de l'intima-media; IVUS, échographie intravasculaire; LEADER, Lower Extremity Arterial Disease Event Reduction Trial; LOCAT, Lopid Coronary Angiography Trial; MI, infarctus du myocarde; NR non rapporté; RADIANCE, Rating Atherosclerotic Disease Change by Imaging with a New CETP Inhibitor Trial; SCRIP, Stanford Coronary Risk Intervention Project; AIT, attaque ischémique transitoire; VA-HIT, Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial; WHO, World Health Organization.; ACV attaque cérébrovasculaire

^a Le décès correspond à la mortalité globale.